From kinetics to dynamics: Are there differences between ACE inhibitors?

European Heart Journal

Volumn 18, Issue SUPPL.5, 1997, Pages

  Reid, J L ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

ACE inhibitors; Heart failure; Hypertension; Hypotension; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRAPRIL; ZOFENOPRIL;

BLOOD PRESSURE MONITORING; CONFERENCE PAPER; COUGHING; DRUG ABSORPTION; DRUG ELIMINATION; ENZYME INHIBITION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEINASE INHIBITION; PROTEINURIA; RASH; TASTE DISORDER;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; PRODRUGS;

EID: 0030668782     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(97)90004-X     Document Type: Article

References (26)

1. Brunner HR, Waebber B, Nussberger J. Angiotensin converting enzyme inhibitors. In: Messerli F, ed. Cardiovascular Drug Therapy, 2nd edn. Philadelphia: W.B. Saunders, 1996: 670-700.
2. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35.
3. British National Formulary. Cardiovascular system - drugs affecting the renin angiotensin system, No. 32, 1996; 80-90.
4. McMurray J, Chopra M. Influence of ACE inhibitors on free radical and reperfusion injury. Br J Clin Pharmacol 1991; 31: 373-9.
5. Cooper WD, Sheldon D, Brown D, Kimber GR. Postmarketing surveillance of enalapril: experience in 11 710 patients in general practice. J Royal Coll Gen Pract 1987; 37: 346-9.
6. Migdalof BH, Antonaccio MJ, McKinstry D et al. Captopril: pharmacology, metabolism and disposition. Drug Metab Rev 1984; 15: 841-69.
7. Gomez HJ, Sromorsky J, Kristianson K. Lisinopril dose response in mild to moderate hypertension. Clin Pharmacol Ther 1985; 37: 198.
8. Ulm EH, Hichens M, Gomez HJ. Enalapril maleate and a lysine analogue: disposition in man. Br J Clin Pharmacol 1982; 14: 357-62.
9. MacFadyen RJ, Lees KR, Reid JL. Perindopril: a review of its pharmacokinetics and clinical pharmacology. Drugs 1990; 39: 49-63.
10. Tsai HH, Lees KR, Howden CW, Reid JL. The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis. Br J Clin Pharmacol 1989; 28: 53-9.
11. Harrigan JR, Hughes DM, Meredith PA, Reid JL. Characterization of the effects of prodrug concentration on the in vivo potency of the metabolites of five ACE inhibitors. Eur J Clin Pharmacol 1989; 36 (Suppl): A186.
12. Johnston CI. Angiotensin converting enzyme inhibitors. In: Doyle AE, eds. Clinical Pharmacology of Antihypertensive Drugs. Handbook of Hypertension, Vol II. Amsterdam: Elsevier Science Publishers, 1988; 301-26.
13. Ryan JW, Chung A, Berryer P, Murray MA, Ryan JPA. Slow tight binding inhibitors of angiotensin converting enzyme. Adv Exp Med Biol 1986; 198: 419-25.
14. Lees KR, Kelman AW, Reid JL, Whiting B. Pharmacokinetic of an ACE inhibitor S9780 in man: Evidence of tissue binding. J Pharmacokinet Biopharm 1989; 17: 529-50.
15. Donnelly R, Meredith PA, Elliott HL, Reid JL. Kinetic dynamic relations and individual responses to enalapril. Hypertension 1990; 15: 301-9.
16. Meredith PA, Elliott HL, Donnelly R, Reid JL. Dose response clarification in early drug development. J Hypertens 1991; 9 (Suppl 6): 356-7.
17. Seymour AA, Assad MM, Abboa-Offei B, Smith PL, Rogers WL, Dorso CR. Determinants of in vivo activity of neutral endopeptidase and angiotensin converting enzyme inhibitors. J Pharmacol Exp Ther 1996; 276: 708-13.
18. Lacourcière Y, Brunner HR, Irwin R, Karlberg BE, Ramsay LE. Effects of modulators of the renin-angiotensin aldosterone system on cough. J Hypertension 1994; 12: 1387-93.
19. Israili ZH, Hall WD. Cough and angioneurotic edema associated with ACE inhibitor therapy - a review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-42.
20. Saruta T, Omae T, Kuramuchi M, Iimura O. Imidapril hydrochloride in essential hypertension: a double blind comparative study using enalapril maleate as a control. J Hypertens 1995; 13 (Suppl 3): 23-30.
21. Swedberg K, Held P, Kjekshus J, Rasmussen P, Ryden L, Weach H. Effects of early administration of enalapril in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II. N Engl J Med 1992; 327: 678-84.
22. Reid J, Lees KR, Squire I. First dose hypotension and ACE inhibitors in heart failure, Chester, England: ADIS International, 1995; 1-23.
23. MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to ACE inhibition in congestive cardiac failure: a placebo controlled study. Br Heart J 1991; 66: 206-11.
24. Squire IB, MacFadyen RJ, Lees KR, Meredith PA, Hillis WS, Reid JL. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. Br J Clin Pharmacol 1994; 38: 117-23.
25. Squire IB, MacFadyen RJ, Lees KR, Reid JL. Differing BP and renin angiotensin system responses to ACE inhibition in heart failure (Abstr). Am Congr Cardiol Atlanta, 1994.
26. MacFadyen RJ, Barr CS, Sturrock NDC, Fenwick M, Struthers AD. Further evidence that chronic perindopril treatment maintains neurohumoral suppression but does not lower blood pressure in chronic cardiac failure. Br J Clin Pharmacol 1997 (in press).